Nik Ding

Has grant

Clinical lecturer

Imperial College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Nik Ding is a Clinical Lecturer at Imperial College in the UK. His research primarily focuses on innovative management strategies for inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Recent publications include contributions to understanding perianal fistulizing conditions, bowel preparation quality, and the implications of body composition assessment in therapeutic responses. Dr. Ding is dedicated to advancing both medical and surgical care approaches within this field.

Recent Grants

Grant: Close

Metabonomics and IBD

Open Date: 2014-07-01

Close Date:

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Collaborators (3)

Michael A. Kamm

AUSTRALIA

View details

Olga Niewiadomski

University of Melbourne

AUSTRALIA

View details

Fernando Gomollón

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nik Ding

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Editorial: Where to Start in Ulcerative Colitis?

Management of Perianal Fistulizing Crohn's Disease According to Principles of Wound Repair

Letter: Bowel Preparation Quality in Patients With Crohn's Disease

A new protocolized treatment strategy optimizing medical and surgical care leads to improved healing of Crohn's perianal fistulas

Diagnosing Crohn's disease in presumed cryptoglandular perianal fistulas: an expert Delphi consensus on early identification of patients at risk of Crohn's disease in perianal fistulas (PREFAB)

MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease

Perianal Fistulizing Crohn's Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions

6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy

Letter: Muscle thickness measurement using ultrasound—A step closer to the use of body composition analysis in the management of inflammatory bowel disease

Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease

ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease

Editorial: improving the use of Montreal classification through a bidirectional approach

Prevalence of NUDT15 Genetic Variants and Incidence of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Letter: diagnostic delay in inflammatory bowel disease

Letter: tofacitinib in the real world – do clinical trial data stand up?

Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease

Systematic review: efficacy of escalated maintenance anti‐tumour necrosis factor therapy in Crohn's disease

Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib

Collaborators (3)

Michael A. Kamm

Olga Niewiadomski

Fernando Gomollón

Make your next move.